Remy Cointreau reported a smaller-than-anticipated fall in its fourth-quarter sales. The luxury spirits maker, known for its premium cognacs such as Remy Martin, announced on Friday that its cognac division saw "significant growth" in China.
According to Reuters, this growth has propelled the division's performance beyond analyst expectations despite facing harsh conditions in its major markets, including China and the United States.
Performance Exceeds Expectations
Analysts had predicted a 3.4% decline in organic sales for the quarter ending in March, with cognac sales expected to remain flat at 0.5%. Contrary to these projections, Remy Cointreau's organic cognac sales soared by 15.4%, resulting in a group-level sales decrease of just 0.7%. The company attributed this remarkable outcome to an "excellent" performance in China, bolstered by favorable phasing effects and marketing initiatives during the Lunar New Year celebrations in February.
US Market Challenges Persist
Yahoo reported that despite the upbeat news from China, Remy Cointreau continued to experience difficulties in the United States. The aftermath of COVID-19's extraordinary sales has waned, leading U.S. retailers and wholesalers to trim down on expensive liquors in their inventories.
The quarter saw "major destocking" in the U.S., exacerbated by phasing effects and increased promotional activities from competitors. Consequently, sales in the Americas plummeted by 39.6% over the entire year, in stark contrast to the 2% growth in the Asia Pacific and a modest 0.7% increase in Europe.
Year-End Financials
Remy Cointreau's group organic sales for the fiscal year stood at 1.19 billion euros, marking a 19.2% decline from the previous year. However, these figures slightly surpassed analyst expectations, shedding a light of optimism on the spirit maker's resilience amidst challenging market conditions.
The strong performance in China, specifically during key festive periods, underscores the strategic importance of market-specific initiatives and the potential for recovery from global market volatility.
Photo: Delightin Dee/Unsplash


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Italy Fines Apple €98.6 Million Over App Store Dominance
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 



